Want to see DSGN full AI Analyst Report?
DSGN Stock Chart & Stats
$15.59
$0.10(0.85%)
At close: 4:00 PM EDT
$15.59
$0.10(0.85%)
Day’s Range― - ―
52-Week Range$5.28 - $17.25
Previous Close$11.88
Volume323.09K
Average Volume (3M)700.51K
Market Cap
$665.87M
Enterprise Value$699.72M
Total Cash (Recent Filing)$207.40M
Total Debt (Recent Filing)$2.03M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 11, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding62,581,650
10 Day Avg. Volume613,620
30 Day Avg. Volume700,515
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.53
Price to Sales (P/S)0.00
P/FCF Ratio-9.86
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.69
Forecast
1Y Price Target
$26.11Price Target Upside67.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform DifferentiationThe GeneTAC platform targets a defined biological cause of serious repeat-expansion diseases by modulating pathogenic DNA sequences and reducing harmful RNA and protein products. This focused mechanism could support a differentiated pipeline and reusable development approach across multiple genetic disorders.
Clinical Pipeline ProgressPositive Phase 1/2 clinical and biomarker findings, together with stated intent to pursue a registrational path for DT-216P2, represent meaningful progress toward a potentially pivotal development stage. Advancing the lead program can improve pipeline credibility and create a clearer route toward future commercialization.
Low Financial LeverageVery low debt reduces fixed financial obligations and gives Design greater flexibility than a highly leveraged development-stage company. The sizable equity base provides resources to continue advancing clinical programs, although its effectiveness depends on how long it can support operations amid ongoing losses.
Bears Say
Pre-Revenue LossesDesign remains entirely pre-revenue while absorbing substantial recurring expenses, with TTM losses of roughly $70.8 million and no evidence of operating leverage. Until a program produces commercial revenue, profitability depends on clinical execution and continued access to funding rather than an established earnings stream.
Persistent Cash BurnPersistently negative operating and free cash flow show that the business is consuming cash to fund research and development rather than generating internal capital. If revenue does not materialize, continued clinical investment will require the company to draw down resources or obtain additional financing over time.
Declining Equity BaseThe substantial decline in equity alongside materially negative returns on equity indicates that accumulated capital is being consumed without producing positive returns. This reduces the financial cushion available for prolonged development and makes future funding efficiency increasingly important to long-term business durability.
Design Therapeutics News
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $5.28 and its highest was $17.25 in the past 12 months.
What is Design Therapeutics’s market cap?
Design Therapeutics’s market cap is $665.87M.
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on Aug 03, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.344 by $0.024.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 62,581,650 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.344. Following the earnings report the stock price went up 4.762%.
Which hedge fund is a major shareholder of Design Therapeutics?
Currently, no hedge funds are holding shares in DSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Design Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.11 (67.47% Upside)
$26.11 (67.47% Upside)
Blogger Sentiment
Bullish
DSGN Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
85.36%
12-Months-Change
Fundamentals
Return on Equity
-34.03%
Trailing 12-Months
Asset Growth
-3.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Design Therapeutics
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
DSGN Stock 12 Month Forecast
Average Price Target
$26.11
▲(67.47% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
10.98%
Insiders
6.21% Mutual Funds
41.83% Other Institutional Investors
31.11% Public Companies and
Individual Investors